Roche’s Tocilizumab neglects to meet essential end focuses for COVID-19 related pneumonia Kumar Jeetendra | July 29, 2020 Swiss Drug maker Roche on July 29 declared that its drug Actemra (Tocilizumab), which has emerged as a widely prescribed drug for treating hosiptalised COVID-19 patients, didn’t fulfill its primary endpoint of improved clinical standing in hospitalised adult patients with acute COVID-19 related pneumonia. In addition, the primary secondary endpoint of decreased patient mortality week …
